rybelsus 14 mg semaglutide Health Canada approves Rybelsus, the first oral GLP-1 pill to lower cardiovascular risk in adults with Type 2 diabetes. #longevity #GLP1 #diabetes #cardiometabolic #hearthealth #metabolichealth #obesitycare #digitalhealth #biotechnews #healthinnovation Rybelsus: Side Effects and How

Oral orfoglipron, as opposed to peptide-based oral semaglutide, can be taken without regard to food timing

Vitamin D3: bone, joint, cardiovascular, and metabolism health

Amylin inhibits postprandial glucagon secretion, delays gastric emptying, and reduces energy intake by acting as a satiation signal to limit meal size (Fig

Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP: Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting

Active gallbladder disease should be addressed before starting weight loss medication